Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on March 26, 2009

Arteriosclerosis, Thrombosis, and Vascular Biology. 2009
Published online before print March 26, 2009, doi: 10.1161/ATVBAHA.108.178541
A more recent version of this article appeared on June 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correction (v29,pe132)
Right arrow All Versions of this Article:
29/6/909    most recent
ATVBAHA.108.178541v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayashi, H.
Right arrow Articles by Kaneda, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayashi, H.
Right arrow Articles by Kaneda, Y.

Submitted on October 7, 2008
Accepted on March 8, 2009

FHL-2 Suppresses VEGF-Induced Phosphatidylinositol 3-Kinase/Akt Activation via Interaction With Sphingosine Kinase-1

Hiroki Hayashi ; Hironori Nakagami *; Yoichi Takami ; Hiroshi Koriyama ; Masaki Mori ; Katsuto Tamai ; Jianxin Sun ; Kaori Nagao ; Ryuichi Morishita ; and Yasufumi Kaneda

From the Division of Gene Therapy Science (H.H., H.N., Y.T., H.K., M.M., K.T., Y.K.), the Department of Geriatric Medicine (Y.T., H.K.), and the Division of Clinical Gene Therapy and Graduate School of Medicine (K.N., R.M.), Osaka University, Japan; and the Department of Cell Biology and Molecular Medicine (J.S.), UMDNJ-New Jersey Medical School, Newark.

* To whom correspondence should be addressed. E-mail: nakagami{at}gts.med.osaka-u.ac.jp.

Objective—In the functional screening of a human heart cDNA library to identify a novel antiangiogenic factor, the prime candidate gene was "four-and-a-half LIM only protein-2" (FHL-2). The goal of this study is to clear the mechanism of antiangiogenic signaling of FHL-2 in endothelial cells (ECs).

Methods and Results—Overexpressed FHL-2 strongly inhibited vascular endothelial growth factor (VEGF)-induced EC migration. In the angiogenic signaling, we focused on sphingosine kinase-1 (SK1), which produces sphingosine-1-phosphate (S1P), a bioactive sphingolipid, as a potent angiogenic mediator in ECs. Immunoprecipitation and immunostaining analysis showed that FHL-2 might bind to SK1. Importantly, overexpression of FHL-2 in ECs inhibited VEGF-induced SK1 activity, phosphatidylinositol 3-kinase activity, and phosphorylation of Akt and eNOS. In contrast, overexpression of FHL-2 had no effect on S1P-induced Akt phosphorylation. Interestingly, VEGF stimulation decreased the binding of FHL-2 and SK1. Depletion of FHL-2 by siRNA increased EC migration accompanied with SK1 and Akt activation, and increased the expression of VEGF receptor-2 which further enhanced VEGF signaling. Furthermore, injection of FHL-2 mRNA into Xenopus embryos resulted in inhibition of vascular network development, assessed by in situ hybridization with endothelial markers.

Conclusions—FHL-2 may regulate phosphatidylinositol 3-kinase/Akt via direct suppression of the SK1-S1P pathway in ECs.


Key words: FHL-2 • VEGF • sphingosine kinase-1 • endothelial cells • Akt pathway